Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial
- O'Donoghue, ML
- Braunwald, Eugene
- White, Harvey D
- Steen, Dylan P
- Lukas, Mary Ann
- Tarka, Elizabeth
- Steg, P. Gabriel
- Hochman, Judith S
- Bode, Christoph
- Maggioni, Aldo P
- Im, Kyungah
- Shannon, Jennifer B
- Davies, Richard Y
- Murphy, Sabina A
- Crugnale, Sharon E
- Wiviott, Stephen D
- Bonaca, Marc P
- Watson, David F
- Weaver, W. Douglas
- Serruys, Patrick W
- Cannon, Christopher P
- ESPOSITO, GIOVANNI
- Steen Dylan L.
DOIAbstract
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme
Add to ORKG